Somato® (Phytomelatonin) Versus Synthetic Melatonin and Placebo on Sleep Quality

Completed · Not applicable · Has a placebo group

Conditions studied: Sleep

In brief

This study examines the effects of a plant-based phytomelatonin supplement compared to synthetic melatonin and placebo in adults with suboptimal sleep quality. The research uses a randomized, double-blind, placebo-controlled, three-arm clinical trial design. The primary aim is to determine whether phytomelatonin improves sleep outcomes compared to placebo and whether it matches or exceeds synthetic melatonin. Participants will be randomly assigned to receive 2 mg phytomelatonin, 10 mg synthetic melatonin, or an inactive placebo. Each participant will take one capsule nightly for 28 days. Objective sleep metrics will be captured continuously using the Oura Ring wearable device. Subjective outcomes will be measured at baseline and post-intervention using validated surveys such as the Pittsburgh Sleep Quality Index and the SF-36. Weekly visual analog scales will assess morning grogginess. Safety, tolerability, and user experience differences between groups will also be evaluated.

Key facts

Study ID

NCT07669766

Run by

Nutraland USA, Inc.

People needed

244

Starts

2026-01-13

Expected to finish

2026-04-17

Last updated by the study team

2026-06-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Device Compliance: Willingness to consistently wear an Oura Ring Gen3 and maintain an active membership throughout the study duration.
• Baseline Sleep Score: A baseline Oura sleep score of less than 75, indicating sub-optimal sleep quality.
• Oura Ring Usage History: Demonstrated at least 80% adherence to Oura Ring use during the 30 days prior to enrollment.
• Health and Supplement Stability: No significant changes in dietary supplement use or medical history within the past 30 days, to ensure stability in baseline physiological and health conditions.

You may not qualify if…

• Current or recent use (within the past 30 days) of any sleep-promoting dietary supplement.
• Current or recent use (within the past 30 days) of any sleep-promoting medications, whether prescription or over-the-counter.
• Pregnant or breastfeeding women will be excluded from the study.
• Substance Use Disorder: Individuals with a history of drug or alcohol dependency who have not maintained sobriety for a minimum of the past 12 months.
• Severe Medical Conditions: Presence of severe or unstable medical conditions that may interfere with study participation or outcomes.
• Use of Mood-Affecting Medications: Use of any medications known to significantly influence mood, circadian rhythms, or melatonin pathways.
• Sensitivity to Nightshades: Known sensitivity or allergy to nightshade plants, including tomatoes, due to the nature of the study intervention.

Where it is running

• N/A Decentralized Trial - address for CRO headquarters, not the study location — Wilmington, Delaware, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.